TORONTO, ONTARIO--(Marketwired - May 28, 2014) - Stem Cell Therapeutics Corp. ("SCT") (TSX:SSS)(OTCQX:SCTPF), an immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that the company's annual and special meeting of shareholders held yesterday voted to support all of the resolutions proposed to shareholders.
Each of the seven proposed directors was elected: Dr. Calvin Stiller, Mr. Luke Beshar, Dr. Henry Friesen, Dr. Robert Kirkman, Dr. Michael Moore, Dr. Thomas Reynolds and Dr. Niclas Stiernholm. The shareholders also voted to approve the company's amended and restated stock option, deferred share unit and shareholder rights plans.
Shareholders also supported the change of the company's name to Trillium Therapeutics Inc., the approval of two administrative by-law resolutions, and agreed to provide the Board of Directors with the authority to consolidate the outstanding common shares.
About Stem Cell Therapeutics:
Stem Cell Therapeutics Corp. is an immuno-oncology company developing innovative therapies for the treatment of cancer. The Company has two premier preclinical programs, SIRPaFc and a CD200 monoclonal antibody (mAb), which target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on cancer stem cells in AML and several other tumors. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors. SCT's clinical stage programs include tigecycline which is being evaluated in a multi-centre Phase I study in patients with acute myeloid leukemia (AML), and TTI-1612 that has completed a 28-patient Phase I trial in interstitial cystitis ("IC") patients. For more information, visit: www.stemcellthera.com
Caution Regarding Forward-Looking Information:
This press release may contain forward-looking statements, which reflect SCT's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include changing market conditions; the successful and timely completion of pre-clinical and clinical studies; the establishment of corporate alliances; the impact of competitive products and pricing; new product development risks; uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in SCT's ongoing quarterly and annual reporting. Except as required by applicable securities laws, SCT undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
FOR FURTHER INFORMATION PLEASE CONTACT:
Stem Cell Therapeutics Corp.James Parsons
Chief Financial Officer
+1 416 595 0627
Source: Stem Cell Therapeutics Corp.